Bovista Gigantea Liquid (S#186) 1 X Liquid is a Health Canada–registered human drug (DIN 02201453) held by Total Health Centre, containing Bovista. Health Canada lists its status as Cancelled Post Market (status date 05 Aug 2009). Nexara Health has matched 8 registrations of Bovista across 1 other regulated market.
Health Canada registration
| DIN | 02201453 |
|---|---|
| Brand name | Bovista Gigantea Liquid (S#186) |
| Active ingredient | Bovista |
| Strength | 1 X |
| Dosage form | Liquid |
| Route | Sublingual |
| Company | Total Health Centre |
| Status | Cancelled Post Market — 05 Aug 2009 |
| Class | Human |
| ATC | |
| AHFS | 92:02.00* ; See footnote |
| Regulator record | Health Canada DPD entry · Product monograph |
Bovista registered in other markets
8 registrations of the same molecule in 1 national registry outside Canada. Each row is taken from the regulator's own published list; status is shown as the registry reports it.
| Country | Product | Marketing authorisation holder | Strength | Form | Status | Registry |
|---|---|---|---|---|---|---|
| United States | Bovista | Hahnemann Laboratories, INC. | Pellet | listed | FDA NDC | |
| United States | Bovista | Hahnemann Laboratories, INC. | Pellet | listed | FDA NDC | |
| United States | Bovista | Hahnemann Laboratories, INC. | Pellet | listed | FDA NDC | |
| United States | Bovista | Hahnemann Laboratories, INC. | Pellet | listed | FDA NDC | |
| United States | Bovista | Hahnemann Laboratories, INC. | Pellet | listed | FDA NDC | |
| United States | Bovista | Hahnemann Laboratories, INC. | Pellet | listed | FDA NDC | |
| United States | Bovista | Hahnemann Laboratories, INC. | Pellet | listed | FDA NDC | |
| United States | Bovista | Ohm Pharma Inc. | Pellet | listed | FDA NDC |
See every manufacturer of Bovista worldwide →
Sourcing through Nexara Health
Nexara Health is a Health Canada–licensed wholesaler (DEL #3-002896) in Winnipeg. This DIN is not currently marketed in Canada. The registrations above show which regulated markets hold an equivalent presentation that can be sourced for clinical comparator use or on a named-patient basis under Health Canada's Special Access Programme. Request a quote or read how named-patient and foreign-pack supply works in Canada.
Frequently asked questions
Is Bovista Gigantea Liquid (S#186) (DIN 02201453) marketed in Canada?
No. Health Canada lists DIN 02201453 as Cancelled Post Market as of 05 Aug 2009.
Who holds the Canadian licence for this product?
Total Health Centre is the company of record in the Health Canada Drug Product Database.
Is Bovista registered outside Canada?
Yes — Nexara Health has matched 8 registrations in 1 other market (see the table above).
Where does this data come from?
Health Canada Drug Product Database (DPD), DIN 02201453, status date 2009-08-05; national medicine registries: FDA NDC. Nexara Health re-checks these sources weekly and shows the last verification date at the top of the page.
Source: Health Canada Drug Product Database (DPD), DIN 02201453, status date 2009-08-05; national medicine registries: FDA NDC.
Health Canada Drug Product Database (DPD), DIN 02201453, status date 2009-08-05; national medicine registries: FDA NDC. Last reviewed 2026-09-16. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.